MYC and breast carcinoma: Compound 44 also showed the ability to inhibit c-MYC transcription in a concentration-dependent manner and had weaker effects in other oncogenes’ transcriptions, which shows the preference to silence the c-MYC gene in the breast cancer 4T1 cell line.